<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125549</url>
  </required_header>
  <id_info>
    <org_study_id>FK-CLP</org_study_id>
    <nct_id>NCT05125549</nct_id>
  </id_info>
  <brief_title>Fasted Bioequivalence Study of Clopidogrel Film-coated Tablets, 75 mg in 48 Healthy, Adult Male and Female Subjects.</brief_title>
  <official_title>Fasting, Comparative, Open-label, Randomized, Four-period, Two-sequence, Bioequivalence Study of Сlopidogrel Bisulfate Film-coated Tablets, 75 mg (JSC Farmak, Ukraine) vs Plavix® 75 mg Film-coated Tablets in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joint Stock Company &quot;Farmak&quot;</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Joint Stock Company &quot;Farmak&quot;</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to compare bioequivalence of the Test Product Clopidogrel bisulfate,&#xD;
      film-coated tablets, 75 mg (JSC Farmak, Ukraine) and Reference Product Plavix® 75 mg&#xD;
      film-coated tablets (Sanofi Winthrop Industrie, France) in healthy male and female volunteers&#xD;
      under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open, comparative, randomized, four-period, two- sequence, two-way crossover clinical&#xD;
      trial to evaluate the Bioequivalence of Single Doses of Test Product Clopidogrel bisulfate,&#xD;
      film-coated tablets, 75 mg (JSC Farmak, Ukraine) and Reference Product Plavix® 75 mg&#xD;
      film-coated tablets (Sanofi Winthrop Industrie, France) in healthy adult male and female&#xD;
      volunteers under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Actual">August 27, 2018</completion_date>
  <primary_completion_date type="Actual">August 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Сmax</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>maximum plasma concentration observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>area under the plasma concentration versus time curve calculated by the trapezoidal rule from sampling time zero to sampling time of the last measurable plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>the time of the maximum plasma drug concentration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>λz</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>apparent first-order elimination</description>
  </other_outcome>
  <other_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>the elimination or terminal half-life</description>
  </other_outcome>
  <other_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>area under the plasma concentration versus time curve from time zero to infinity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)</intervention_name>
    <description>One film-coated tablet was administrated orally with 240 ml of water after an overnight fast</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Trombonet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)</intervention_name>
    <description>One film-coated tablet was administrated orally with 240 ml of water after an overnight fast</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and non-pregnant and no breast-feeding females1), ≥18 and ≤50 years of&#xD;
             age (on the day of Informed Consent). Caucasian race.&#xD;
&#xD;
          -  Subject had provided his/her written informed consent before the start of any&#xD;
             screening procedures.&#xD;
&#xD;
          -  Subject was available for the whole study and to follow all the requirements of the&#xD;
             study protocol.&#xD;
&#xD;
          -  Body Mass Index (BMI) 18.5 to 30.0 kg/m2, inclusive (on the day of screening).&#xD;
&#xD;
          -  Subject without any acute or chronic diseases of the cardiovascular system,&#xD;
             neuroendocrine system, kidney, liver, gastrointestinal tract, respiratory system.&#xD;
&#xD;
          -  Subjects in good health, as determined by screening medical history, physical&#xD;
             examination, vital signs assessments (pulse rate, systolic and diastolic blood&#xD;
             pressure, and body temperature) and 12-lead electrocardiogram (ECG). Minor deviations&#xD;
             outside the reference ranges were acceptable, if deemed not clinically significant by&#xD;
             the Investigator&#xD;
&#xD;
          -  The results of fluorography are within normal ranges (no more than 10 months before&#xD;
             inclusion in the study).&#xD;
&#xD;
          -  Sitting blood pressure is within normal ranges: 100 -140 mm Hg for systolic PB, 55 -95&#xD;
             mm Hg. for diastolic blood pressure (BP) at screening;&#xD;
&#xD;
          -  Acceptance of use of contraceptive measures during the whole study by both female and&#xD;
             male subjects.&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  Subject is available to comply with the general dietary restrictions throughout the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe allergy or allergic reactions to the study Investigational Medicinal&#xD;
             Product (IMP), its excipients or related drugs.&#xD;
&#xD;
          -  Aggravated allergic history&#xD;
&#xD;
          -  History of any clinically significant disease or disorder or surgical intervention&#xD;
             which, in the opinion of the Investigator, may either put the subject at risk because&#xD;
             of participation in the study, or influence the results or the subject's ability to&#xD;
             participate in the study.&#xD;
&#xD;
          -  A positive result of Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), and&#xD;
             / or (human immunodeficiency virus) HIV or syphilis tests during screening procedure.&#xD;
&#xD;
          -  A positive results of urine drug of abuse test (amphetamine, methamphetamine,&#xD;
             morphine, marijuana, cocaine).&#xD;
&#xD;
          -  Positive result of alcohol breath test&#xD;
&#xD;
          -  Positive urine cotinine test&#xD;
&#xD;
          -  The values of the standard parameters of the laboratory and instrumental examinations&#xD;
             are outside the normal range and are clinically relevant or require additional&#xD;
             examination and interpretation.&#xD;
&#xD;
          -  Pregnancy (positive urine pregnancy test result in women)&#xD;
&#xD;
          -  Lactation period (for women).&#xD;
&#xD;
          -  Acute infectious diseases in less than 28 days before the first dosing.&#xD;
&#xD;
          -  Use of any medication for a period of 14 days before the first dosing.&#xD;
&#xD;
          -  Donation of blood within 30 days before the first dosing.&#xD;
&#xD;
          -  Participation in any other clinical study during last 90 days.&#xD;
&#xD;
          -  Other reasons when participation of a volunteer in the study is undesirable in the&#xD;
             opinion of the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vlad Udovytskyi</last_name>
    <role>Study Chair</role>
    <affiliation>Joint Stock Company &quot;Farmak&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Diagnostics Center of National University of Pharmacy (NUPh).</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>generic drugs</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Film-coated Tablets</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

